Primary and acquired resistance to anti-EGFR targeted drugs in cancer therapy

In recent years, the epidermal growth factor receptor (EGFR) has been recognized as a central player and regulator of cancer cell proliferation, apoptosis and angiogenesis and, therefore, as a potentially relevant therapeutic target. Several strategies for EGFR targeting have been developed, the mos...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Differentiation (London) 2007-11, Vol.75 (9), p.788-799
Hauptverfasser:	Morgillo, Floriana, Bareschino, Maria Anna, Bianco, Roberto, Tortora, Giampaolo, Ciardiello, Fortunato
Format:	Artikel
Sprache:	eng
Schlagworte:	Antineoplastic Agents - therapeutic use cetuximab Drug Resistance, Neoplasm EGFR pathways erlotinib gefitinib Humans Neoplasms - drug therapy Neoplasms - enzymology Protein Kinase Inhibitors - therapeutic use Receptor, Epidermal Growth Factor - antagonists & inhibitors resistance
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!